Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy

Pediatric Transplantation

Volumn 11, Issue 5, 2007, Pages 481-490

  Hedman, Mia ^a   Pahlman, Raija ^a   Sundvall, Jouko ^a   Ehnholm, Christian ^a   Syvänne, Mikko ^b   Jokinen, Eero ^a   Jauhiainen, Matti ^a   Holmberg, Christer ^a   Antikainen, Marjatta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

apoB; HDL; Lipoproteins; Pediatric heart transplantation; Pravastatin; Transplant vasculopathy

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B100; AZATHIOPRINE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; MEPREDNISONE; PRAVASTATIN; STEROID; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC GRAFT REJECTION; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; LIPID COMPOSITION; MALE; PREDICTION; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, HDL; COLORIMETRY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; INFANT; MALE; POSTOPERATIVE COMPLICATIONS; PRAVASTATIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRACENTRIFUGATION;

EID: 34447325959     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00690.x     Document Type: Article

References (70)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the international society of heart and lung transplantation: Twenty-second official adult heart transplant report - 2005. J Heart Lung Tranplant 2005 : 24 : 945 955.
2. Boucek MM, Edwards LB, Keck BM, et al. Registry of the international society of heart and lung transplantation: Eight official pediatric report-2005. J Heart Lung Tranplant 2005 : 24 : 968 982.
3. St. Goar FG, Pint FI, Alderman EL, et al. Intracoronary ultrasound in cardiac transplant recipients: In vivo evidence of angiographically silent intimal thickening. Circulation 1992 : 85 : 979 987.
4. Rickenbacher PR, Pinto FI, Chenzbraun A, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995 : 25 : 171 177.
5. Rickenbacher PR, Kemna MS, Pinto FJ, et al. Coronary artery intimal thickening in the transplanted heart: An in vivo intracoronary ultrasound study of immunologic and metabolic risk factors. Transplantation 1996 : 61 : 46 53.
6. Valantine H, Pinto FJ, St. Goar FG, Alderman EL, Popp RL. Intracoronary ultrasound imaging in heart transplant recipients: The Stanford experience. J Heart Lung Transplant 1992 : 11 : S60 S64.
7. Kobashigawa JA. Coronary artery disease in the transplanted heart: Why does it happen and what can we do about it? Cardiol Rev 1996 : 4 : 1 11.
8. Kobashigawa JA. Statins in solid organ transplantation: Is there an immunosuppressive effect? Am J Transplant 2004 : 4 : 1012 1018.
9. Pahl E, Naftel DC, Kuhn MA, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: A 9-year multi-institutional study. J Heart Lung Transplant 2005 : 24 : 645 651.
10. Hathout E, Beeson WL, Kuhn M, et al. Cardiac allograft vasculopathy in pediatric heart transplant recipients. Transpl Int 2006 : 19 : 184 189.
11. Braudin EA, Hunter DW, Canter CE, et al. Coronary artery disease in pediatric transplant recipients receiving triple-drug immunosuppression. Circulation 1991 : 84 (Suppl. 5 303 309.
12. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989 : 261 : 3561 3566.
13. Perrault LP, Mahlberg F, Breugnot C, et al. Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation. Arterioscler Thromb Vasc Biol 2000 : 20 : 728 736.
14. Hoang K, Chen YD, Reaven G, et al. Diabetes and dyslipidemia: A new model for transplant coronary artery disease. Circulation 1998 : 97 : 2160 2168.
15. Park JW, Merz M, Braun P, et al. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 1996 : 15 : 572 579.
16. Weis M, von Scheidt W. Cardiac allograft vasculopathy: A review. Circulation 1997 : 96 : 2069 2077.
17. Chin C, Rosenthal D, Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 2000 : 4 : 193 199.
18. Valantine H, Rickenbacker P, Kemna M, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: A prospective study. Circulation 2001 : 103 : 2144 2152.
19. Hauptman JW, Davis SF, Miller L, Yeung AC. The multicenter intravascular ultrasound transplant study group. The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: Preliminary insights from a multicenter intravascular ultrasound study. J Heart Lung Transplant 1995 : 14 : S238 S242.
20. Lietz K, John R, Burke EA, et al. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation 2001 : 72 : 277 283.
21. Kemna MS, Valantine HA, Hunt SA, et al. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 1994 : 128 : 68 72.
22. Valantine HA. Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant ''atheroma.'' Transplantation 2003 : 76 : 891 899.
23. Ballantyne CM, Radovancevic R, Farmer JA, et al. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992 : 19 : 1315 1321.
24. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: Initial experience with pravastatin. J Heart Lung Transplant 2004 : 23 : 317 322.
25. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987 : 76 : 827 834.
26. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practise. JAMA 1992 : 267 : 961 968.
27. Siirtola A, Antikainen M, Ala-Houhala M, et al. Studies of LDL particle size and susceptibility to oxidation and association with glucose metabolism in children after heart transplantation. J Heart Lung Transplant 2004 : 23 : 418 426.
28. Armstrong AK, Goldberg CS, Crowley DC, Gajarski RJ. Effect of age on lipid profiles in pediatric heart transplant recipients. Pediatr Transplant 2005 : 9 : 523 530.
29. Siirtola A, Antikainen M, Ala-Houhtala M, et al. Serum lipids in children 3 to 5 years after kidney, liver and heart transplantation. Transplant Int 2004 : 17 : 109 119.
30. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995 : 333 : 621 627.
31. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomised trial. Circulation 1997 : 96 : 1398 1402.
32. Weis M, Pehlivanli S, Meiser BM, et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. Am J Cardiol 2001 : 38 : 814 818.
33. Mehra MR, Raval NY. Meta-analysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004 : 36 : 1539 1541.
34. Bilchick KC, Henricson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004 : 148 : 200 210.
35. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial o pravastatin in heart transplant patients. J Heart Lung Transplant 2005 : 24 : 1736 1740.
36. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990 : 82 : IV281 IV283.
37. Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000 : 19 : 529 537.
38. Wenke K, Meiser B, Thiery T, Reichart B. Impact of simvastatin therapy after heart transplantation. An 11-year prospective evaluation. Herz 2005 : 5 : 431 432.
39. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002 : 40 : 1609 1614.
40. Magnani G, Carinci V, Magelli C, et al. Role of statins in the management of dyslipidemias after cardiac transplant: Randomized, controlled trial comparing the efficacy and safety of atorvastatin with pravastatin. J Heart Lung Transplant 2000 : 19 : 710 715.
41. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001 20 : 611 618.
42. Samman A, Imai C, Straatman L, et al. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. J Heart Lung Transplant 2005 : 24 : 1008 1013.
43. Chin C, Gamberg P, Miller J, Luikart H, Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 2002 : 21 : 1213 1217.
44. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: Report of two cases in cardiac transplant recipients. JAMA 1988 260 : 239 241.
45. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on triple immunosuppression. Clin Pharmacol Ther 2004 : 75 : 101 109.
46. Park J-W, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharm Ther 2002 : 40 : 439 450.
47. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993 25 : 2732 2734.
48. Kobashigawa JA. Postoperative management following heart transplantation. Transplant Proc 1999 : 31 : 2038 2046.
49. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group: The international society for heart transplantation. J Heart Transplant 1990 : 9 : 587 593.
50. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 : 18 : 499 502.
51. Takayama M, Itoh S, Nagasaki T, Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta 1977 79 : 93 98.
52. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003 : 361 : 777 780.
53. von Eckardstein A, Nofer J-R, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001 : 21 : 13 27.
54. Wilson PW. Established risk factors and coronary disease: The Framingham Study. Am J Hypertens 1994 : 7 : 7S 12S.
55. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 : 124 Suppl : S11 S20.
56. Linsel-Nitsche P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005 : 4 : 193 205.
57. Cockerill GW, Rye K-A, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995 : 15 : 1987 1994.
58. Cockerill GW, Saklatvala J, Ridley SH, et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999 : 19 : 910 917.
59. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentrations reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001 : 103 : 108 112.
60. Speidel MT, Booyse FM, Abrams A, Moore MA, Chung BH. Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoproteins inhibit this cytotoxicity. Thromb Res 1990 : 58 : 251 264.
61. Walldius G, Jungner I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001 : 358 : 2026 2033.
62. Talmud PJ, Hawe E, Miller GJ, Humphries EE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002 : 22 : 1918 1923.
63. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratio to estimate the balance between proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004 : 42 : 1355 1363.
64. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005 : 24 : 63 66.
65. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 : 335 : 1001 1009.
66. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 : 333 : 1301 1307.
67. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 : 339 : 1349 1357.
68. Wenke K. Management of hyperlipidemia associated with heart transplantation. Drugs 2004 : 64 : 1053 1068.
69. Laroia ST, Ganti AK, Laroia AT, Tendulkar KK. Endothelium and the lipid metabolism: The current understanding. Int J Cardiol 2003 : 88 : 1 9.
70. Vorlat A, Conraads VM, Vrints CJ. Regular use of margarine-containing stanol/sterol esters reduces total and low-density lipoprotein (LDL) cholesterol and allows reduction of statin therapy after cardiac transplantation: Preliminary observations. J Heart Lung Transplant 2003 : 22 : 1059 1062.